This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sirard, J. C. Articles by Mock, M. Search for Related Content PubMed PubMed Citation Articles by Sirard, J. C. Articles by Mock, M.

 Previous Article  |  Next Article 

Infect. Immun., 06 1997, 2029-2033, Vol 65, No. 6
Copyright © 1997, American Society for Microbiology

A recombinant Bacillus anthracis strain producing the Clostridium perfringens Ib component induces protection against iota toxins

JC Sirard, M Weber, E Duflot, MR Popoff and M Mock
Unite des Toxines et Pathogenie Bacteriennes, URA1858, Centre National de la Recherche Scientifique, Institut Pasteur, Paris, France.jcsirard@pasteur.fr

The Bacillus anthracis toxinogenic Sterne strain is currently used as a live veterinary vaccine against anthrax. The capacity of a toxin- deficient derivative strain to produce a heterologous antigen by using the strong inducible promoter of the B. anthracis pag gene was investigated. The expression of the foreign gene ibp, encoding the Ib component of iota toxin from Clostridium perfringens, was analyzed. A pag-ibp fusion was introduced by allelic exchange into a toxin- deficient Sterne strain, thereby replacing the wild-type pag gene. This recombinant strain, called BAIB, was stable and secreted large quantities of Ib protein in induced culture conditions. Mice given injections of live BAIB spores developed an antibody response specific to the Ib protein. The pag-ibp fusion was therefore functional both in vitro and in vivo. Moreover, the immunized animals were protected against a challenge with C. perfringens iota toxin or with the homologous Clostridium spiroforme toxin. The protective immunity was mediated by neutralizing antibodies. In conclusion, B. anthracis is promising for the development of live veterinary vaccines.

This article has been cited by other articles:

• Barth, H., Aktories, K., Popoff, M. R., Stiles, B. G. (2004). Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins. Microbiol. Mol. Biol. Rev. 68: 373-402 [Abstract] [Full Text]  
• Blocker, D., Behlke, J., Aktories, K., Barth, H. (2001). Cellular Uptake of the Clostridium perfringens Binary Iota-Toxin. Infect. Immun. 69: 2980-2987 [Abstract] [Full Text]  
• Brossier, F., Weber-Levy, M., Mock, M., Sirard, J.-C. (2000). Protective Antigen-Mediated Antibody Response against a Heterologous Protein Produced In Vivo by Bacillus anthracis. Infect. Immun. 68: 5731-5734 [Abstract] [Full Text]  
• Mesnage, S., Weber-Levy, M., Haustant, M., Mock, M., Fouet, A. (1999). Cell Surface-Exposed Tetanus Toxin Fragment C Produced by Recombinant Bacillus anthracis Protects against Tetanus Toxin. Infect. Immun. 67: 4847-4850 [Abstract] [Full Text]